JP2010500375A - 活性剤の多段階送達 - Google Patents

活性剤の多段階送達 Download PDF

Info

Publication number
JP2010500375A
JP2010500375A JP2009523983A JP2009523983A JP2010500375A JP 2010500375 A JP2010500375 A JP 2010500375A JP 2009523983 A JP2009523983 A JP 2009523983A JP 2009523983 A JP2009523983 A JP 2009523983A JP 2010500375 A JP2010500375 A JP 2010500375A
Authority
JP
Japan
Prior art keywords
stage
particles
particle
composition
stage particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009523983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500375A5 (https=
Inventor
フェラーリ，マウロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2010500375A publication Critical patent/JP2010500375A/ja
Publication of JP2010500375A5 publication Critical patent/JP2010500375A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009523983A 2006-08-08 2007-08-08 活性剤の多段階送達 Pending JP2010500375A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82175006P 2006-08-08 2006-08-08
US91434807P 2007-04-27 2007-04-27
PCT/US2007/075516 WO2008021908A2 (en) 2006-08-08 2007-08-08 Multistage delivery of active agents

Publications (2)

Publication Number Publication Date
JP2010500375A true JP2010500375A (ja) 2010-01-07
JP2010500375A5 JP2010500375A5 (https=) 2010-09-24

Family

ID=39082940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523983A Pending JP2010500375A (ja) 2006-08-08 2007-08-08 活性剤の多段階送達

Country Status (8)

Country Link
US (4) US20080311182A1 (https=)
EP (1) EP2056794A4 (https=)
JP (1) JP2010500375A (https=)
CN (1) CN101652126B (https=)
AU (1) AU2007286203B2 (https=)
CA (1) CA2664919A1 (https=)
MX (1) MX2009001461A (https=)
WO (1) WO2008021908A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537540A (ja) * 2010-08-16 2013-10-03 オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション 生体分子を送達するためのセラミック粒子を含む粒子状物質
JP2015536319A (ja) * 2012-10-16 2015-12-21 ウィリアム・マーシュ・ライス・ユニバーシティ 薬剤耐性を克服するための改善されたナノベクターベースの薬物送達システム
JP2018519347A (ja) * 2015-07-09 2018-07-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合性リポソーム被覆多孔質ケイ素ナノ粒子
JP2019510085A (ja) * 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
JP2020504177A (ja) * 2017-01-04 2020-02-06 ナノティックス，エルエルシー 捕捉粒子をアセンブルするための方法

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033679A2 (en) 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
US7854944B2 (en) * 2004-12-17 2010-12-21 Advanced Cardiovascular Systems, Inc. Tissue regeneration
CA2648581A1 (en) 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
US8563022B2 (en) * 2006-10-11 2013-10-22 Board Of Regents Of The University Of Texas System Particles for cell targeting
WO2008106350A1 (en) * 2007-02-26 2008-09-04 Board Of Regents Of The University Of Texas System Endocytotic particles
US8920625B2 (en) 2007-04-27 2014-12-30 Board Of Regents Of The University Of Texas System Electrochemical method of making porous particles using a constant current density
CA2722183C (en) * 2008-04-25 2018-09-18 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
US8173115B2 (en) 2008-07-29 2012-05-08 The Board Of Regents Of The University Of Texas System Particle compositions with a pre-selected cell internalization mode
CA2732252A1 (en) * 2008-07-29 2010-02-04 Paolo Decuzzi Particle compositions with a pre-selected cell internalization mode
US20110213193A1 (en) * 2008-08-28 2011-09-01 The Florida International University Board Of Trustees Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier
EP2373292A1 (en) * 2008-12-23 2011-10-12 Board of Regents of the University of Texas System Inflammation targeting particles
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20120045396A1 (en) * 2009-01-15 2012-02-23 Board Of Regents Of The University Of Texas System Porous structures with modified biodegradation kinetics
EP2398462A4 (en) * 2009-02-18 2012-07-25 Aradigm Corp PH-MODULATED FORMULATIONS FOR PULMONARY ADMINISTRATION
US8808733B2 (en) 2009-03-31 2014-08-19 The Board Of Trustees Of The University Of Arkansas Method of controlled drug release from a liposome carrier
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
BRPI1011269A2 (pt) * 2009-05-05 2016-09-27 Altermune Technologies Llc imunidade quimicamente programável
FR2948024B1 (fr) * 2009-07-17 2020-01-10 Centre National De La Recherche Scientifique - Cnrs - Emulsion activable par ultrasons et son procede de fabrication.
CA2775324C (en) * 2009-09-23 2018-05-15 Crystalplex Corporation Passivated nanoparticles
ES2367959B1 (es) * 2009-12-22 2013-01-24 Centro De Investigación Biomédica En Red En Bioingeniería, Biomateriales Y Nanomedicina Particulas magnético-luminiscentes para aplicaciones biomédicas.
WO2011091065A2 (en) 2010-01-19 2011-07-28 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
CN102858367B (zh) 2010-02-26 2014-12-17 国立大学法人长崎大学 抗原或药物递送复合物
US8568877B2 (en) 2010-03-09 2013-10-29 Board Of Regents Of The University Of Texas System Porous and non-porous nanostructures
WO2011116237A1 (en) * 2010-03-17 2011-09-22 Board Of Regents Of The University Of Texas System Universal cell-directed theranostics
EP2590605A1 (en) 2010-07-09 2013-05-15 Board of Regents of the University of Texas System Biodegradable scaffolds
US20130224282A1 (en) * 2010-09-21 2013-08-29 Massachusetts Institute Of Technology Multistage Nanoparticles
RU2475233C2 (ru) * 2010-12-01 2013-02-20 Учреждение Российской академии наук Институт кристаллографии им. А.В. Шубникова РАН Фармакологическая композиция, предназначенная для интраназального введения с целью доставки в мозг фармакологически активного компонента, и способ ее получения
EP2697162B1 (en) 2011-04-14 2020-12-02 The Regents of The University of California Multifunctional nanoparticle designs and applications
CN103998932B (zh) 2011-06-29 2017-06-06 中央研究院 使用表面涂层对生物物质的捕获、纯化和释放
US9101547B2 (en) 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
US8859004B2 (en) 2011-08-04 2014-10-14 Nano And Advanced Materials Institute Limited pH-sensitive nanoparticles for oral insulin delivery
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
WO2013095736A2 (en) * 2011-09-27 2013-06-27 The Methodist Hospital Research Institute Gold-in-silicon nanoassembly for thermal therapy and methods of use
WO2013070872A1 (en) 2011-11-08 2013-05-16 The Board Of Trustees Of The University Of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
US8926994B2 (en) * 2011-12-07 2015-01-06 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
US20130304050A1 (en) * 2012-05-10 2013-11-14 Wake Forest University Health Sciences Methods of treating cancerous tissue
US10842749B2 (en) * 2012-06-12 2020-11-24 The Methodist Hospital Research Institute Compositions and methods of treating therapy resistant cancer and uses thereof
US8883216B2 (en) 2012-08-27 2014-11-11 Red Lion Chem Tech, Llc Methods and ceramic nanoparticle compositions for heavy metal removal and for oral delivery of desirable agents
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
US20170136123A1 (en) * 2013-01-10 2017-05-18 Amrita Vishwa Vidyapeetham Stannous doped micro and nano particles for augmented radiofrequency ablation
JP2015007209A (ja) * 2013-05-31 2015-01-15 株式会社リコー コアシェル型粒子、及びその製造方法
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
WO2015023797A1 (en) 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
US20160279187A1 (en) * 2013-10-31 2016-09-29 University Of Hawaii Calpain inhibitors for ibd and colorectal cancer treatment
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
WO2015153816A2 (en) 2014-04-01 2015-10-08 Academia Sinica Methods and systems for cancer diagnosis and prognosis
WO2015176025A1 (en) 2014-05-15 2015-11-19 The Methodist Hospital Discoidal polymeric nanoconstructs and methods of use in cancer theranostics
EP3971262B1 (en) 2014-05-29 2024-04-24 Tectus Corporation Dispersion system for quantum dots
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3173074A4 (en) 2014-07-22 2018-03-07 Lemonex Inc. Composition for delivering bioactive material or protein, and use thereof
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
MX2017003903A (es) 2014-10-03 2017-09-15 Ntercept Llc Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
CA2963931A1 (en) 2014-10-06 2016-04-14 Exicure, Inc. Anti-tnf compounds
KR20170078843A (ko) 2014-11-21 2017-07-07 노오쓰웨스턴 유니버시티 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
US20170056327A1 (en) * 2015-08-25 2017-03-02 The Methodist Hospital Micro/nano composite drug delivery formulations and uses thereof
ITUB20159209A1 (it) 2015-12-21 2017-06-21 Fidia Farm Spa Nanosistemi per il trasporto controllato di molecole attive a fini diagnostici, prognostici e terapeutici
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA
US20190177615A1 (en) 2016-05-19 2019-06-13 Crystalplex Corporation Cadmium-free quantum dots, tunable quantum dots, quantum dot containing polymer, articles, films, and 3d structure containing them and methods of making and using them
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
KR20180091768A (ko) 2017-02-06 2018-08-16 주식회사 레모넥스 생리활성물질 전달체
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
JP2020526558A (ja) 2017-07-13 2020-08-31 ノースウェスタン ユニバーシティ オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
US20200163885A1 (en) * 2017-07-25 2020-05-28 Lemonex Inc. Composition for delivering physiologically active ingredients into blood vessel
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
KR102729931B1 (ko) 2017-12-19 2024-11-13 나노비오?笭? 신경 장애의 치료에서 사용하기 위한 나노입자
EP4461363A3 (en) 2017-12-19 2025-01-08 Nanobiotix Nanoparticles for use in enhancing brain performances or in treating stress
WO2019157319A1 (en) * 2018-02-12 2019-08-15 Flagship Pioneering Innovations V, Inc. Devices and methods for delivering material into a biological tissue or cell
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
CN112546406B (zh) * 2020-11-20 2022-04-22 广东药科大学 一种微型机器人给药装置及给药系统
WO2024035784A1 (en) * 2022-08-10 2024-02-15 Auburn University Shrinking nanomaterial for biomedical applications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10203964A (ja) * 1997-01-16 1998-08-04 Lipotec Sa 難吸収性薬剤の経口生物学的利用能を改善する新しい調剤
WO2004082660A1 (en) * 2003-03-13 2004-09-30 Salvona Llc A controlled release system for pharmaceutical food and nutraceutical use
WO2005009602A2 (en) * 2003-07-22 2005-02-03 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
WO2005084710A2 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888176A (en) 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
US4933185A (en) 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US6099864A (en) 1994-12-02 2000-08-08 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration In situ activation of microcapsules
US6107102A (en) 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
US6395302B1 (en) * 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
WO2000030592A1 (en) * 1998-11-20 2000-06-02 The General Hospital Corporation Permanent, removable tissue markings
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US20030114366A1 (en) * 1999-01-11 2003-06-19 Francis J. Martin Microfabricated particles and method for treating solid tumors
US6685927B2 (en) * 2001-09-27 2004-02-03 Ceramoptec Industries, Inc. Topical application of chromophores for hair removal
US8753897B2 (en) 2005-12-20 2014-06-17 The Board Of Regents Of The University Of Texas System Nanoporous substrates for the analytical methods
US20090311295A1 (en) * 2006-05-12 2009-12-17 Edith Mathiowitz Particles with high uniform loading of nanoparticles and methods of preparation thereof
WO2008041970A2 (en) * 2006-09-28 2008-04-10 Board Of Regents Of The University Of Texas System Methods and compositions for targeting fenestrated vasculature
US8563022B2 (en) * 2006-10-11 2013-10-22 Board Of Regents Of The University Of Texas System Particles for cell targeting
US8920625B2 (en) * 2007-04-27 2014-12-30 Board Of Regents Of The University Of Texas System Electrochemical method of making porous particles using a constant current density

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10203964A (ja) * 1997-01-16 1998-08-04 Lipotec Sa 難吸収性薬剤の経口生物学的利用能を改善する新しい調剤
WO2004082660A1 (en) * 2003-03-13 2004-09-30 Salvona Llc A controlled release system for pharmaceutical food and nutraceutical use
WO2005009602A2 (en) * 2003-07-22 2005-02-03 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
WO2005084710A2 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537540A (ja) * 2010-08-16 2013-10-03 オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション 生体分子を送達するためのセラミック粒子を含む粒子状物質
JP2015536319A (ja) * 2012-10-16 2015-12-21 ウィリアム・マーシュ・ライス・ユニバーシティ 薬剤耐性を克服するための改善されたナノベクターベースの薬物送達システム
JP2018519347A (ja) * 2015-07-09 2018-07-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合性リポソーム被覆多孔質ケイ素ナノ粒子
JP2019510085A (ja) * 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
JP2020504177A (ja) * 2017-01-04 2020-02-06 ナノティックス，エルエルシー 捕捉粒子をアセンブルするための方法
JP2023075293A (ja) * 2017-01-04 2023-05-30 ナノティックス，エルエルシー 捕捉粒子をアセンブルするための方法

Also Published As

Publication number Publication date
US20080311182A1 (en) 2008-12-18
CN101652126A (zh) 2010-02-17
EP2056794A2 (en) 2009-05-13
AU2007286203B2 (en) 2013-05-02
CN101652126B (zh) 2013-07-17
WO2008021908A2 (en) 2008-02-21
CA2664919A1 (en) 2008-02-21
US20160051481A1 (en) 2016-02-25
MX2009001461A (es) 2009-07-02
AU2007286203A1 (en) 2008-02-21
EP2056794A4 (en) 2012-12-26
AU2007286203A2 (en) 2009-03-19
HK1140139A1 (zh) 2010-10-08
WO2008021908A3 (en) 2008-08-14
US10143658B2 (en) 2018-12-04
US20190111000A1 (en) 2019-04-18
US20210338593A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
US20210338593A1 (en) Multistage delivery of active agents
Ashfaq et al. Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment
Bhatia Nanoparticles types, classification, characterization, fabrication methods and drug delivery applications
Li et al. Tailoring porous silicon for biomedical applications: from drug delivery to cancer immunotherapy
Swain et al. Nanoparticles for cancer targeting: current and future directions
Athar et al. Therapeutic nanoparticles: State-of-the-art of nanomedicine
Kim et al. Nanomedicine for targeted drug delivery
Mao et al. Gold nanospheres and nanorods for anti-cancer therapy: comparative studies of fabrication, surface-decoration, and anti-cancer treatments
A Santos et al. Multifunctional porous silicon for therapeutic drug delivery and imaging
Fattal et al. Nanomedicine technology: current achievements and new trends
Mahato Multifunctional micro-and nanoparticles
Naik Nano based drug delivery
Hnawate et al. Nanoparticle-novel drug delivery system: A Review
CN102264353A (zh) 炎症靶向颗粒
Kasar et al. Nanoplex: a review of nanotechnology approach for solubility and dissolution rate enhancement
Ferrari et al. Multistage delivery of active agents
Jain Nanopharmaceuticals
Ezegbe et al. Drug carriers
Barbosa et al. Nanotechnology applied in drug delivery
Le et al. Applications of nanometre scale particles as pharmaceutical delivery vehicles in medicine
HK1140139B (en) Multistage delivery of active agents
Shitole et al. Nanoparticle-Novel Drug Delivery System: A Review
Singh et al. 5. Nanomedicine strategies: a precise therapeutic approach for disease
Vijayakumar et al. Nanomedicine for cancer targeted drug delivery, early detection mechanism and therapeutics
Jain Nanopharmaceuticals

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100318

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100806

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130307

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140715